The key message of the document is that CytomX will be more financially stable in 2025. has become more financially stablebut at the same time Varseta-M and CX-801 clearly positioned as the main strategic programs. All facts are taken from your open PDF ir.cytomx.com.
📌 Key points of the document
🧬 1. progress in the Varseta-M program (CRC)
- Positive phase 1 data in advanced colorectal cancer.
- Target 2026: Coordination with the FDA on a registrational study design.
- Combination studies underway or starting in 2026:
- Varseta-M + bevacizumab (phase 1 started).
- Varseta-M + Chemo + Bevacizumab (Phase 1b/2 planned until the end of 2026).
- Extension to further EpCAM-positive tumors from 2H 2026.
🧪 2. progress in the CX-801 program (melanoma)
- Phase 1 monotherapy achieved 4th dose level, well tolerated.
- Combination with KEYTRUDA® in dose escalation since 2025.
- First efficacy data of the combination expected end of 2026.
- Biomarker data support mechanism and combination.
💼 3. financial position 2025
- Cash position at the end of 2025: USD 137.1 million (previous year: USD 100.6 million).
- Cash runway until Q2 2027.
- Decline in salesUSD 76.2 million (2025) vs. USD 138.1 million (2024), mainly due to concluded BMS cooperation.
- Costs reduced:
- R&D: USD 68.7 million (-14.7 million vs. 2024).
- G&A stable at ~29.8 m USD.
- Net loss 2025: -17.4m USD (2024: +31.9m profit).
🤝 4. partnerships & pipeline
- Active collaborations with Bristol Myers Squibb, Amgen, Regeneron, Moderna.
- Astellas terminated remaining preclinical programs (effective Q2 2026).
- Pipeline includes ADCs, cytokines, T-cell engagers.
🧭 5. strategic direction 2026
- Top priority: Move Varseta-M towards approval.
- Acceleration of combination therapies for earlier CRC lines.
- CX-801 positioned as a potential new building block for immunotherapy.
- Focus on lean cost structure and targeted pipeline.
🧾 6. key financial figures (excerpt)
- Total assets: USD 151.6 million.
- Equity: USD 99.0 million (previous year: USD -0.5 million).
- Deferred revenue fell sharply (from 94 million to 28 million), reflecting the completed partner milestones.
🎯 Summary
CytomX enters the year with stronger balance sheetclear pipeline focus and promising promising Varseta-M data. success now depends to a large extent on the FDA approval. FDA approval and the combination studies studies.